Understanding the unique aspects of immunotherapy for lung cancer

Understanding the unique aspects of immunotherapy for lung cancer

EMJ

3 years
503 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses the efficacy and safety of immunotherapy for patients with non-small cell lung cancer. Promising agents include the anti-PD1 antibodies, nivolumab and pembrolizumab; the anti-PD-L1 antibodies, atezolizumab, durvalumab and avelumab; and anti-CTLA-4 antibodies, ipilimumab and tremelimumab. Challenges exist with determining how these immunotherapy approaches can be integrated in clinical practice, in order to, for example, exploit their favourable toxicity profile while avoiding immune-related adverse events. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
869 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
2 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
6 Views
EMJ 3 years
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Category: Acute Lymphoblastic Leukemia
595 Views
EMJ 3 years
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
Category: Acute Lymphoblastic Leukemia
933 Views
EMJ 3 years
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
Category: Acute Lymphoblastic Leukemia
539 Views
EMJ 3 years
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Category: Acute Lymphoblastic Leukemia
594 Views
EMJ 3 years
Addressing inequalities and unmet needs in breast cancer patients
Addressing inequalities and unmet needs in breast cancer patients
Category: Acute Lymphoblastic Leukemia
500 Views
EMJ 3 years
Breast cancer in Europe: Epidemiology and improving outcomes
Breast cancer in Europe: Epidemiology and improving outcomes
Category: Acute Lymphoblastic Leukemia
431 Views
EMJ 3 years
2005–2015 global analysis of advanced breast cancer
2005–2015 global analysis of advanced breast cancer
Category: Acute Lymphoblastic Leukemia
517 Views
EMJ 3 years